HomeCompareNTST vs ZBH

NTST vs ZBH: Dividend Comparison 2026

NTST yields 4.52% · ZBH yields 1.08%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NTST wins by $7.45M in total portfolio value
10 years
NTST
NTST
● Live price
4.52%
Share price
$19.04
Annual div
$0.86
5Y div CAGR
67.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.48M
Annual income
$5,955,978.20
Full NTST calculator →
ZBH
ZBH
● Live price
1.08%
Share price
$88.62
Annual div
$0.96
5Y div CAGR
0.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.2K
Annual income
$118.64
Full ZBH calculator →

Portfolio growth — NTST vs ZBH

📍 NTST pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNTSTZBH
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NTST + ZBH cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NTST pays
ZBH pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NTST
Annual income on $10K today (after 15% tax)
$383.93/yr
After 10yr DRIP, annual income (after tax)
$5,062,581.47/yr
ZBH
Annual income on $10K today (after 15% tax)
$92.08/yr
After 10yr DRIP, annual income (after tax)
$100.84/yr
At 15% tax rate, NTST beats the other by $5,062,480.63/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NTST + ZBH for your $10,000?

NTST: 50%ZBH: 50%
100% ZBH50/50100% NTST
Portfolio after 10yr
$3.75M
Annual income
$2,978,048.42/yr
Blended yield
79.45%
📊

Analyst Conviction Gap

Where Wall Street is split right now

NTST
Analyst Ratings
14
Buy
4
Hold
Consensus: Buy
Price Target
$21.17
+11.2% upside vs current
Range: $19.00 — $22.00
Altman Z
0.9
Piotroski
7/9
ZBH
Analyst Ratings
17
Buy
21
Hold
3
Sell
Consensus: Hold
Price Target
$105.60
+19.2% upside vs current
Range: $89.00 — $122.00
Altman Z
1.7
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NTST buys
1
ZBH buys
0
PoliticianChamberTickerTypeAmountDate
Chris Jacobs🏢 House$NTST▲ Buy$1,001 - $15,0002022-12-12
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNTSTZBH
Forward yield4.52%1.08%
Annual dividend / share$0.86$0.96
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR67.2%0.2%
Portfolio after 10y$7.48M$21.2K
Annual income after 10y$5,955,978.20$118.64
Total dividends collected$7.32M$1.1K
Payment frequencyquarterlyquarterly
SectorREITHealthcare
Analyst consensusBuyHold
Analyst price target$21.17$105.60

Year-by-year: NTST vs ZBH ($10,000, DRIP)

YearNTST PortfolioNTST Income/yrZBH PortfolioZBH Income/yrGap
1← crossover$11,455$755.21$10,809$108.54+$646.00NTST
2$13,609$1,351.83$11,675$109.86+$1.9KNTST
3$17,071$2,509.55$12,603$111.13+$4.5KNTST
4$23,185$4,919.11$13,598$112.34+$9.6KNTST
5$35,248$10,439.70$14,663$113.51+$20.6KNTST
6$62,516$24,800.62$15,804$114.62+$46.7KNTST
7$135,626$68,734.15$17,026$115.69+$118.6KNTST
8$378,132$233,012.05$18,335$116.71+$359.8KNTST
9$1,419,753$1,015,152.05$19,736$117.70+$1.40MNTST
10$7,475,114$5,955,978.20$21,236$118.64+$7.45MNTST

NTST vs ZBH: Complete Analysis 2026

NTSTREIT

NETSTREIT is an internally managed Real Estate Investment Trust (REIT) based in Dallas, Texas that specializes in acquiring single-tenant net lease retail properties nationwide. The growing portfolio consists of high-quality properties leased to e-commerce resistant tenants with healthy balance sheets. Led by a management team of seasoned commercial real estate executives, NETSTREIT's strategy is to create the highest quality net lease retail portfolio in the country with the goal of generating consistent cash flows and dividends for its investors.

Full NTST Calculator →

ZBHHealthcare

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Full ZBH Calculator →
📬

Get this NTST vs ZBH comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NTST vs SCHDNTST vs JEPINTST vs ONTST vs KONTST vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.